The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Grigorian O.R.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii, Moskva

Andreeva E.N.

Mediko-geneticheskoe otdelenie Moskovskogo oblastnogo NII akusherstva i ginekologii

Melnichenko G.A.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
Endocrinology Research Center, Ministry of Health of Russia, Moscow, Russia

Dedov I.I.

Endocrinology Research Centre

The influence of metformin on amh level in obese patients with pcos

Authors:

Grigorian O.R., Andreeva E.N., Melnichenko G.A., Dedov I.I.

More about the authors

Journal: Russian Journal of Human Reproduction. 2013;(1): 39‑41

Read: 16135 times

Download PDF (RU)
Contact the author
Table of contents

THE INFLUENCE OF METFORMIN ON AMH LEVEL IN OBESE PATIENTS WITH PCOS
THE INFLUENCE OF METFORMIN ON AMH LEVEL IN OBESE PATIENTS WITH PCOS

To cite this article:

Grigorian OR, Andreeva EN, Melnichenko GA, Dedov II. The influence of metformin on amh level in obese patients with pcos. Russian Journal of Human Reproduction. 2013;(1):39‑41. (In Russ.)

 
Подписка 2026 Проблемы репродукции (Russian Journal of Human Reproduction)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A personalized approach to the diagnosis of epilepsy in obese children. Labo­ratory Service. 2025;(1):5-12
Dietary restrictions as a risk factor for binge eating diso­rder. Russian Journal of Preventive Medi­cine. 2025;(4):123-129
Obesity in the context of the «old friends» hypo­thesis. Russian Journal of Preventive Medi­cine. 2025;(4):136-141
Premature birth and obesity: epidemiology, pathogenesis and obstetric tactics. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):29-34
Treatment and prevention of suture failure and bleeding after various bariatric inte­rventions. Piro­gov Russian Journal of Surgery. 2025;(5):79-85
Prevalence of meta­bolic syndrome among the indi­genous popu­lation in central Yaku­tia rural areas. Russian Journal of Preventive Medi­cine. 2025;(5):21-26
Drinking mine­ral water for progressive resi­stance to insu­lin. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):24-30
Analysis of the different approaches effe­ctiveness to the treatment of patients with obesity. Russian Journal of Preventive Medi­cine. 2025;(6):120-125
Sarcopenia index for dete­cting of the decreased muscle stre­ngth and mass in patients with the non-alcoholic fatty liver disease. Russian Journal of Preventive Medi­cine. 2025;(7):68-74
Ethnic aspe­cts of risk factors for the type 2 diabetes mellitus deve­lopment in the overweight women of the Pribaikalsky region. Russian Journal of Preventive Medi­cine. 2025;(8):56-62
Abstract:

Decreasing of AMH level in females with hyperinsulinemia after metformine therapy can lead to the conclusion that metformine influences on AMH level and ovulatory dysfunction through insulin mechanism. The idea that AMH level decrease is the consequence of BMI decrease is wrong because normoinsulinemic patients had also BMI decreasing without AMH concentration decrease.

Keywords:

PSOS
obesity
metformine
AM

Authors:

Grigorian O.R.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossii, Moskva

Andreeva E.N.

Mediko-geneticheskoe otdelenie Moskovskogo oblastnogo NII akusherstva i ginekologii

Melnichenko G.A.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia;
Endocrinology Research Center, Ministry of Health of Russia, Moscow, Russia

Dedov I.I.

Endocrinology Research Centre

Close metadata

References:

  1. Carlsen S.M., Vanky E., Fleming R. Anti-Mullerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Human Reprod 2009; 24: 1732-1738.
  2. Coutts J.R., Adam A.H., Fleming R. The deficient luteal phase may represent an anovulatory cycle. Clin Endocrinol (Oxford) 1982; 17: 4: 389-394.
  3. Du Q., Wang Y.J., Yang S., Wu B., Han P., Zhao Y.Y. A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr Med Res Opin 2012; 28: 5: 723-730.
  4. Eldar-Geva T., Margalioth E.J., Gai M., Ben-Chetrit A., Algur N., Zylber-Haran E., Brooks B., Huerta M., Spitz I.M. Serum anti-Mullerianhormone levels during controlled ovarian hyperstimulation in women inpolycystic ovaries with and without hyperandrogenism. Human Reprod 2005; 20: 1814-1819.
  5. Fleming R., Harborne L., MacLaughlin D.T., Ling D., Norman J., Sattar N., Seifer D.B. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril 2005; 83: 130-136.
  6. Jonard S., DeWailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004; 10: 107-117.
  7. La Marca A., Orvieto R., Giulini S., Jasonni V.M., Volpe A., De Leo V. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004; 82: 970-972.
  8. Laven J.S.E., Mulders A.M., Visser J., Themmen A.P., de Jong F.H., Fauser B.C.J.M. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metabol 2004; 89: 318-323.
  9. Nardo L.G., Yates A.P., Roberts S.A., Pemberton P., Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod 2009; 24: 2917-2923.
  10. Pigny P., Merlen E., Robert Y., Cortet-Rudelli C., Decanter C., Jonard S., Dewailley D. Elevated serum level of anti-Müllerian hormone inpatients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicle arrest. J Clin Endocrinol Metabol 2003; 88: 5957-5962.
  11. Piltonen T., Morin-Papunen L., Koivunen R., Perheentupa A., Ruokonen A., Tapanainen J.S. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Human Reprod 2005; 20: 1820-1826.
  12. Piouka A., Farmakiotis D., Katsikis I., Macut D., Gerou S., Panidis D. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Phys Endocrinol Metabol 2009; 296: E238-E243.
  13. Romualdi D., De Cicco S., Tagliaferri V., Proto C., Lanzone A., Guido M. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96: 5: E821-E824.
  14. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47.
  15. Tang T., Lord J.M., Norman R.J., Yasmin E., Balen A.H. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012; 16: 5: CD003053.
  16. Thomson R.L., Buckley J.D., Moran L.J., Noakes M., Clifton P.M., Norman R.J., Brinkworth G.D. The effect of weight loss on anti-Müllerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod 2009; 24: 1976-1981.
  17. Tomova A., Deepinder F., Robeva R., Kirilov G., Mechandjiev Z., Kumanov P. Anti-Müllerian hormone in women with polycystic ovary syndrome before and after therapy withmetformin. Horm Metab Res 2011; 43: 10: 723-727.
  18. Viollet B., Guigas B., Sanz Garcia N., Leclerc J., Foretz M., Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122: 6: 253-270.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.